Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Still Needled By Icahn, Forest Nominates Three To Board

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.

You may also be interested in...

Forest’s Recent Launches Boosting Diversity, But Gaining Traction Slowly

One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.

Deals Of The Week: Stiefel/Welichem, Bayer/Covance, Ensemble/Genentech

Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.

Forest Holds Off Icahn, But Battle Likely Looms

Forest shareholders elect the company's slate of board members at its annual meeting, shooting down activist investor Carl Icahn's picks.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts